Literature DB >> 17597706

Risk factors and hormone-receptor status: epidemiology, risk-prediction models and treatment implications for breast cancer.

Wendy Y Chen1, Graham A Colditz.   

Abstract

It is increasingly being recognized that breast cancer does not represent a single homogeneous disease; instead, the hormone-receptor status defines important clinical and etiologic differences. We review the epidemiologic data on differences in risk-factor associations by hormone-receptor status and highlight major trends in the literature. We discuss the development and evaluation of breast cancer risk models, with a focus on the Rosner and Colditz model, which can separately estimate the risk of hormone-receptor-positive and hormone-receptor-negative breast cancers. We also discuss the clinical implications of accounting for hormone-receptor status in breast cancer risk-prediction models.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17597706     DOI: 10.1038/ncponc0851

Source DB:  PubMed          Journal:  Nat Clin Pract Oncol        ISSN: 1743-4254


  40 in total

Review 1.  Postmenopausal hormone therapy and breast cancer risk: current status and unanswered questions.

Authors:  Wendy Y Chen
Journal:  Endocrinol Metab Clin North Am       Date:  2011-07-12       Impact factor: 4.741

2.  Cigarette smoking, physical activity, and alcohol consumption as predictors of cancer incidence among women at high risk of breast cancer in the NSABP P-1 trial.

Authors:  Stephanie R Land; Qing Liu; D Lawrence Wickerham; Joseph P Costantino; Patricia A Ganz
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2014-02-25       Impact factor: 4.254

3.  Detecting and exploiting etiologic heterogeneity in epidemiologic studies.

Authors:  Colin B Begg; Emily C Zabor
Journal:  Am J Epidemiol       Date:  2012-08-24       Impact factor: 4.897

4.  Previous Midlife Oestradiol Treatment Results in Long-Term Maintenance of Hippocampal Oestrogen Receptor α Levels in Ovariectomised Rats: Mechanisms and Implications for Memory.

Authors:  K L Black; C F Witty; J M Daniel
Journal:  J Neuroendocrinol       Date:  2016-10       Impact factor: 3.627

Review 5.  Mechanisms of resistance to estrogen receptor modulators in ER+/HER2- advanced breast cancer.

Authors:  Jin Zhang; Qianying Wang; Qing Wang; Jiangran Cao; Jiafu Sun; Zhengmao Zhu
Journal:  Cell Mol Life Sci       Date:  2019-08-30       Impact factor: 9.261

6.  Association of hormone-related characteristics and breast cancer risk by estrogen receptor/progesterone receptor status in the shanghai breast cancer study.

Authors:  Ping-Ping Bao; Xiao Ou Shu; Yu-Tang Gao; Ying Zheng; Hui Cai; Sandra L Deming; Zhi-Xian Ruan; Yinghao Su; Kai Gu; Wei Lu; Wei Zheng
Journal:  Am J Epidemiol       Date:  2011-07-18       Impact factor: 4.897

7.  PIK3CA mutations contribute to fulvestrant resistance in ER-positive breast cancer.

Authors:  Doudou Huang; Lin Tang; Fang Yang; Juan Jin; Xiaoxiang Guan
Journal:  Am J Transl Res       Date:  2019-09-15       Impact factor: 4.060

8.  Validation of a breast cancer risk prediction model developed for Black women.

Authors:  Deborah A Boggs; Lynn Rosenberg; Michael J Pencina; Lucile L Adams-Campbell; Julie R Palmer
Journal:  J Natl Cancer Inst       Date:  2013-02-14       Impact factor: 13.506

9.  Consumption of dairy and meat in relation to breast cancer risk in the Black Women's Health Study.

Authors:  Jeanine M Genkinger; Kepher H Makambi; Julie R Palmer; Lynn Rosenberg; Lucile L Adams-Campbell
Journal:  Cancer Causes Control       Date:  2013-01-18       Impact factor: 2.506

Review 10.  Long-term consequences of estrogens administered in midlife on female cognitive aging.

Authors:  Jill M Daniel; Christine F Witty; Shaefali P Rodgers
Journal:  Horm Behav       Date:  2015-04-25       Impact factor: 3.587

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.